Key facts
- Biolinq’s last known valuation is $407.0M (Apr 2025).
- It has raised $312.8M across 8 recorded rounds; the latest was Later Stage VC ($90.0M) in Mar 2025.
- Notable investors include MedTech Innovator, National Institutes of Health, CONNECT(San Diego), Pegasus Tech Ventures, Mark Cuban — 36 tracked in total.
- Biolinq has filed 12 Form Ds with the SEC since 2016, most recently Mar 2025 ($90.0M sold to 45 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 8 rounds
- ·The complete investor list — 36 names
- ·Watchlist + deal alerts for Biolinq
Funding rounds
8 roundsAbout Biolinq
Developer of a biomonitoring health platform designed to improve metabolic health. The company's platform offers a skin-applied, minimally invasive electrochemical biosensor with a potential for multiple analytes, such as glucose, ketones, and lactate, and provides actionable metabolic health insights from multi-analyte wearable sensors, providing patients with personalized health insights and supporting advancements in medicine.
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2012
- Employees
- 111
- Website
- biolinq.com/
- Ownership
- Privately Held (backing)
Biolinq doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Biolinq shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Biolinq in its N-PORT filings yet. We sweep new filings monthly.